Granite Investment Partners’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Granite Investment Partners’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-207,799	Closed	-$14.4M	–	367
2018 Q3	$14.4M	Buy	207,799 +9,025	+5%	+$684K	0.83%	53
2018 Q2	$15M	Buy	198,774 +84,567	+74%	+$5.32M	0.95%	33
2018 Q1	$6.02M	Sell	114,207 -210	-0.2%	-$12.2K	0.4%	97
2017 Q4	$6.11M	Buy	114,417 +3,073	+3%	+$171K	0.39%	99
2017 Q3	$6.64M	Buy	111,344 +20,354	+22%	+$1.23M	0.41%	94
2017 Q2	$7.18M	Buy	+90,990	New	+$7.44M	0.48%	84

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Granite Investment Partners's EGRX Position: Q4 2018 in Review

Granite Investment Partners sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2018, closing a stake of 207,799 shares — an estimated $14.4M sold.

Granite Investment Partners first reported a position in EGRX in Q2 2017 and held it in 6 quarters. The position peaked at $15M in Q2 2018. 182 funds tracked by Wall St. Rank hold EGRX as of Q4 2018.

Granite Investment Partners reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
Granite Investment Partners sold 207,799 Eagle Pharmaceuticals, Inc. shares in Q4 2018, an estimated $14.4M.
Granite Investment Partners first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2017 and held it in 6 quarters.
Granite Investment Partners's Eagle Pharmaceuticals, Inc. position peaked at $15M in Q2 2018.
182 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2018.

Based on Granite Investment Partners's 13F filing for Q4 2018, filed 13 Feb 2019.